The administration of magnesium sulphate is a proposed novel therapy for Irukandji syndrome 1 . In this nonrandomized, unblinded case series, data from ten patients who received magnesium salts are reviewed. Magnesium sulphate boluses of 10 to 20 mmol, in the six patients for which there was adequate data, reduced pain scores immediately after administration from 8.7±1.5 to 2. P=0.03). In ten patients blood pressure decreased with a mean difference of -18 mmHg in mean arterial pressure. Magnesium requirements in individual patients varied markedly. Pain on injection occurred in four patients, three of whom had received peripherally administered magnesium chloride, and one patient reported transient ptosis after administration of magnesium sulphate 166 mmol over 18 hours in the setting of severe Irukandji syndrome.
Irukandji syndrome is a relatively common and problematic envenomation in tropical Australia 2 . It is believed to be caused by envenomation by carybdeid jellyfish, classically Carukia barnesi, but almost certainly several other species are implicated 3 . Patients demonstrate hypertension, diaphoresis, agitation, piloerection, and severe pain typically most prominent in the lower back, abdomen and chest. Symptom control is frequently difficult using opioid analgesics and vasodilators. The clinical features are consistent with a hyperadrenergic state, and animal modelling of Carukia envenomation with whole-animal extract shows markedly elevated systemic noradrenaline levels 4 . Evidence of myocardial injury occurs in about one third of patients presenting to medical attention with this envenomation, and several cases of cardiac failure requiring intensive care interventions have been reported 2, 5 . Irukandji syndrome has been impli-cated in two deaths from intracranial haemorrhage secondary to severe hypertension induced by the envenomation 2, 6 and has been recently reviewed 7 .
Magnesium sulphate (MgSO 4 ) administered by intravenous infusion is a well-established therapy for conditions associated with abnormalities of catecholamine secretion and/or receptor activity, especially pre-eclampsia, phaeochromocytoma resection and the neuronal hyperexcitability syndrome 8 . Consideration of the analogies between these diseases and the Irukandji syndrome led to the hypothesis that magnesium sulphate may have a role in its management. In early 2003 one of the authors reported the use of magnesium sulphate by intravenous infusion in a diver with Irukandji syndrome with apparent efficacy in controlling hyperadrenergic features and somewhat surprisingly, the associated pain 1 .
We report our experience with this novel application of magnesium salts.
METHODS
After initial experience of MgSO 4 was communicated among colleagues in tropical Australia it was requested that case data be prospectively collected for the generation of a case series. The diagnosis and management of Irukandji syndrome and data collected were at the discretion of the treating physicians.
No standardized dosing regimen for magnesium administration was prescribed, though recommendations were for the use of doses based on the range for which there is experience in pre-eclampsia. Careful monitoring of patients was recommended and undertaken in all cases in this series. Pain scores, when available, were collected using a zero to ten ascending verbal scale. Pain scores prior to and after receiving a loading dose of MgSO 4 were assumed to be nonparametric data and compared using a Wilcoxon signed rank test. Blood pressures over time were compared using t-tests for matched pairs. Mean arterial pressure was taken directly from observation charts whenever available. When not available, it was derived by the formula Pmean= Pdiastolic+[(Psystolic-Pdiastolic)/3] and expressed in mmHg.
RESULTS
Information regarding thirteen patients treated for Irukandji syndrome with MgSO 4 or magnesium chloride (MgCl 2 ) infusions was received. Detailed data from ten cases was forwarded and three brief reports received. The ten detailed reports comprised raw patient notes (7 cases) or detailed summaries with observations (3 cases). For the purposes of this series only cases with detailed information were considered other than for brief comment. Seven patients received MgSO 4 and three MgCl 2 . Doses in all cases were based on magnesium ion mass.
Ten reports were from North Queensland and three from Broome. The North Queensland reports were from the typical wet season risk period, with the latest being from March 2003. All three cases reported from Broome occurred in May.
Analgesic effects
Six patients had adequately documented pain scores prior to and after magnesium loading doses. Initial bolus doses were followed in five patients by marked reduction in pain scores and one a minor reduction, augmented by a second 10 mmol bolus. Pain scores (mean±SD) were 8.7±1.5 prior to magnesium loading and 2.8±2.8 immediately after (P=0.03) ( Figure 1 ). In the four charts in which pain scores were not documented the term "improved" is found in all charts in association with drug administration.
Five patients were managed without any opioid analgesia after commencement of a magnesium infusion. Two patients required aliquots of morphine after discontinuation or rapid reduction in magnesium infusion rate. Two patients with severe presenting symptoms (pain score=10 with reductions to 3 and 4 after 10 and 20 mmol MgSO 4 respectively) required significant opioid supplementation during magnesium infusion despite a marked initial response.
In three patients delay in commencing an infusion after the loading dose was associated with recrudescence of symptoms. Recrudescence of symptoms occurred after early discontinuation of the magnesium infusion in three patients, or its abrupt reduction (5 to 1 mmol/h) in one.
Cardiovascular Effects
Blood pressure showed modest but statistically significant reductions after the magnesium loading dose ( Table 1) . No episode of hypotension or electrocardiographic abnormality associated with magnesium administration was reported. Two of the seven patients in whom troponin assays were performed had positive results (peak 2.2 and 4.6 g/l, normal <0.7). Both of these did not receive MgSO 4 until more than six hours post envenomation. No patient developed clinical evidence of myocardial dysfunction.
Doses and administration
Initial loading doses ranged from 5 to 20 mmol. Administration continued for an average of 12.5 hours (range 1.6 to 35 hours, SD 9.7 h), with 5 treatments ending in less than 12 hours due to resolution of symptoms. One treatment was discontinued due to exhaustion of hospital supplies of MgSO 4 .
Adverse Effects
All three patients receiving magnesium chloride and one receiving undiluted magnesium sulphate reported pain on injection. One patient receiving a total of 166 mmol MgSO 4 over 18 hours in the setting of severe envenoming and underlying congenital cardiac disease, reported some ptosis and diplopia, which resolved as the infusion was withdrawn. Deep tendon reflexes, bulbar and respiratory function were preserved and no persistent adverse effects occurred.
Three cases were reported as brief summaries. In two of these magnesium sulphate administration was associated with attenuation of symptoms (Dr D. Farlow, Dr M. Lewis, personal communications). One patient received a 10 mmol load and 5 mmol/h infusion without any evident clinical change and has been reported previously 9 .
DISCUSSION
The data presented above suggest that intravenous magnesium salt boluses followed by infusion may attenuate pain and hypertension in some patients presenting with Irukandji syndrome. As this is an unblinded non-randomized series, we advocate caution in the interpretation of the data. Overall, of thirteen cases, twelve had evidence of early clinical response to magnesium loading. Five patients with clinical Irukandji syndrome were subsequently managed without further opioids once established on a magnesium infusion. It would appear from this case series that a severe presenting clinical syndrome generally mandates the use of concomitant opioids.
A temporal relationship appears to exist between drug administration and perceived reduction in pain. Recurrence of symptoms with early withdrawal of the drug supports a temporal relationship between onset and offset of drug effect and symptoms.
Magnesium ions are central to multiple physiological mechanisms and are intimately involved in potassium and calcium ion fluxes 8, 10 . Magnesium sul-phate has been used as a therapeutic agent in a wide range of conditions but has found clear niches in the management of pre-eclampsia and phaeochromocytoma 10 . In the setting of phaeochromocytoma it is believed to inhibit release of catecholamines due to competitive inhibition of calcium-dependent exocytosis 8, 10 . Magnesium is believed to weakly enhance the analgesic effect of opioids in the perioperative setting 11, 12 .
Magnesium competes with calcium to inhibit release of acetylcholine at the neuromuscular junction and catecholamines at adrenergic and noradrenergic synapses. Magnesium ions are involved in gatekeeping mechanisms at several calcium channels including the N-methyl D-aspartate receptor in which magnesium ions act to preclude calcium influx via the receptor channel 10 .
Without a clear understanding of venom action in Irukandji syndrome, it is highly speculative as to how magnesium could modify its clinical features. Autonomic toxicity via a number of mechanisms is described in the setting of a range of cnidarian envenomations 13 . Carukia barnesi venom has been shown in one model to be a neuronal sodium channel agonist, inhibited by tetrodotoxin 14 . Other cubozoan jellyfish such as Chironex fleckeri and Chiropsalmus quadrigatus produce venoms which appear to increase calcium flux in cardiac and vascular smooth muscle 15, 16 . Some workers consider this to be secondary to sodium influx and inhibited by (Ni ++ ) 17 . Should these mechanisms occur in Irukandji syndrome, inhibition of calcium influx by magnesium ions would offer one mechanism by which magnesium may antagonize venom action, inhibiting noradrenaline and perhaps acetylcholine release. Tetrodotoxin sensitive sodium-calcium channels have recently been described 18 and it is conceivable that common effects may be mediated through this ion channel family.
In a condition in which significant hypertension is a common feature, and approximately one-third of patients show markers of myocardial necrosis, the 20-35% lowering of systemic vascular resistance and increased coronary perfusion seen with clinical doses of magnesium 9 are potentially salutary effects irrespective of any putative antagonism of venom effects.
Safe magnesium sulfate administration in preeclampsia is well established and the majority of patients in this series received doses similar to those used in that condition. Tolerable doses and rates of administration of magnesium sulphate should be determined by careful observation. Attention should be paid to maintenance of blood pressure, preservation of reflexes and signs of neuromuscular blockade, with reduction in infusion rates should this occur. A past history of renal failure or neuromuscular disorders precludes it use under all but the most closely monitored environment. Severe Irukandji syndrome is a clinical situation mandating close monitoring irrespective of the mode of therapy chosen. As magnesium ions inhibit platelet function 8 caution should be exercised in the use of this therapy should established intracranial haemorrhage be suspected.
CONCLUSIONS
In this preliminary, unblinded and non-randomized series, administration of magnesium sulphate appears to be associated with favourable effects on both pain and blood pressure in Irukandji syndrome.
Until more definitive evidence becomes available we do not recommend the routine use of magnesium infusions in Irukandji syndrome. However, clinicians faced with patients suffering persistent symptoms of Irukandji syndrome, with an inadequate response to conventional therapy, may consider the administration of magnesium sulphate. A suggested dose regimen is 10 mmol bolus over 15 minutes, repeated if necessary and followed by an infusion of 5 to 8 mmol/h, titrated to effect and reduced slowly. This should be used in combination with appropriate doses of opioids and the patient monitored carefully.
Randomized controlled trials to assess the efficacy or otherwise of magnesium sulphate in Irukandji syndrome are underway or under ethical review in several centres in tropical Australia. Much work needs to be undertaken at both the basic science and clinical levels to elucidate the organisms responsible for Irukandji syndrome, the molecular actions of the involved venoms and an optimal management strategy.
